EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19

OBJECTIVES: Severe systemic inflammation associated with some stages of COVID-19 and in fatal cases led therapeutic agents developed or used frequently in Rheumatology being at the vanguard of experimental therapeutics strategies. The aim of this project was to elaborate EULAR Points to consider (Pt...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Ann Rheum Dis
Main Authors: Alunno, Alessia, Najm, Aurélie, Machado, Pedro M, Bertheussen, Heidi, Burmester, Gerd R, Carubbi, Francesco, De Marco, Gabriele, Giacomelli, Roberto, Hermine, Olivier, Isaacs, John D, Koné-Paut, Isabelle, Magro-Checa, César, McInnes, Iain, Meroni, Pier Luigi, Quartuccio, Luca, Ramanan, Athimalaipet V, Ramos-Casals, Manuel, Rodríguez Carrio, Javier, Schulze-Koops, Hendrik, Stamm, Tanja A, Tas, Sander W, Terrier, Benjamin, McGonagle, Dennis G, Mariette, Xavier
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2021
נושאים:
Recommendation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7871226/
https://ncbi.nlm.nih.gov/pubmed/33547062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-219724
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים